Loading: 100%
Patheon N.V. logo
no logo available
General Information
Investor relations pageIR page no data available
Founding year no data available
Headquarter , , no data available
Employees 71 (as per Q2 2017)no data available
Sector Biotechnology, HealthcareBiotechnology, Healthcareno data available
Ticker PTIno data available
Financial year endsFY ends End of Octoberno data available
Stock Information (historical prices adjusted for splits and dividends)
Adj. Closing prices (in USD) -Common sharesNov. 16Jan. 17März 17Mai 17Juli 17Sep. 1705101520
datesClosing price (adj.)
13.10.20172.07
11.10.20172.20
04.10.20172.11
27.09.20172.02
20.09.20171.91
13.09.20172.06
06.09.20172.09
30.08.20172.09
23.08.20171.83
16.08.20172.04
09.08.20172.15
02.08.20172.27
26.07.20173.44
19.07.20173.89
12.07.20174.93
05.07.20174.87
27.06.20174.38
20.06.20174.25
13.06.20173.88
06.06.20174.41
30.05.20174.10
23.05.20173.91
16.05.20173.83
09.05.20174.91
02.05.20175.76
25.04.20175.96
18.04.20176.85
11.04.20177.10
04.04.20177.34
28.03.201711.08
21.03.201711.20
14.03.201712.53
07.03.201712.46
28.02.201714.55
21.02.201715.12
14.02.201715.50
07.02.201714.60
31.01.201714.75
24.01.201711.86
17.01.201712.50
10.01.201714.04
03.01.201712.65
27.12.201612.44
19.12.201611.06
12.12.201611.00
05.12.201610.88
28.11.201611.22
21.11.201611.73
14.11.201611.54
07.11.20168.81
31.10.20167.12
24.10.201613.37
17.10.201612.87
no share price data source found
Share price data requested
Key Figures
Last Closing Price
as per Oct 13, 2017, in USD
2.07n/a
Market Capitalisation
in million USD
300n/a
Enterprise Value
in million USD
0n/a
Common Shares Outstanding
as per May 31, 2017
145,136,214n/a
Preferred Shares Outstanding
as per May 31, 2017
n/a
Average Basic Shares Outstanding
TTM
138,690,510n/a
Average Diluted Shares Outstanding
TTM
139,642,153n/a
Index Membership
n/a
Business Summary
Proteostasis Therapeutics Inc operates in the healthcare sector of United States. Its business involves the discovery and development of therapeutics to correct the imbalance of the protein biosynthesis process.
no data available
Key Financials & Ratios (all figures TTM as per , million USD, full statements further below)
Profit & Loss
Revenues 0n/a
Gross Profit 0n/a
Operating Income 0n/a
EBITDA 0n/a
Net Profit 0n/a
Balance Sheet
Cash and Cash Equivalents 0n/a
Receivables 0n/a
Total Current Assets 0n/a
PP&E 0n/a
Total Assets 0n/a
Accounts Payable 0n/a
Current Debt 0n/a
Total Current Liabilities 0n/a
Long-Term Debt 0n/a
Total Liabilities 0n/a
Total Equity 0n/a
Cash Flow
Depreciation & Amortisation 0n/a
Change in Working Capital 0n/a
Operating Cash Flow 0n/a
Net Change in PP&E and Intangibles 0n/a
Investing Cash Flow 0n/a
Dividends Paid 0n/a
Financing Cash Flow 0n/a
Total Change in Cash 0n/a
Free Cash Flow 0n/a
Profitability Ratios
Gross Margin 0.0%n/a
Operating Margin 0.0%n/a
Net Profit Margin 0.0%n/a
Return on Equity 0.0%n/a
Return on Assets 0.0%n/a
Per Share Figures
Basic EPS n/a
Diluted EPS n/a
Sales per Share n/a
Book Value per Share n/a
FCF per Share n/a
Dividends per Share n/a
Price Multiples
Price to Earnings Ratio n/a
Price to Sales Ratio n/a
Price to Book Value n/a
Price to Free Cash Flow n/a
Valuation Metrics
EV/EBITDA n/a
EV/Sales n/a
Book to Market Value n/a
Other Ratios
Current Ratio 0.0%n/a
Liabilities to Equity Ratio 0.0%n/a
Debt to Assets Ratio 0.0%n/a
Profit & Loss StatementP&L data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (5 items missing)
No data available for the selected time periods
in million USD FY '14FY '15FY '16
Revenues
1,484
1,774
1,867
Cost of goods sold
1,096
1,216
1,321
Gross Profit
387
559
546
Selling, general and administrative expenses
239
309
323
Research and development
14
15
2
Repositioning expenses
52
25
7
Acquisition and integration costs
60
19
17
Impairment charge
10
4
0
Other operating loss
0
5
-1
Operating Income
13
182
198
Interest expense, net
91
142
160
Foreign exchange (gain) loss, net
9
18
6
Other income, net
-1
-1
-1
Refinancing expenses
28
4
22
INCOME (LOSS) BEFORE INCOME TAXES
-113
35
11
Gain on sale of third party investment
0
-16
0
Current
20
10
17
Deferred
-15
-10
-41
(Benefit from) provision for income taxes
4
0
-24
Net income (loss) from continuing operations
-117
35
35
Net (loss) income from discontinued operations
-2
104
-3
Net Income (Loss)
-119
138
32
Remarks
restated on Dec 23, 2016 n/a
calculated values,
restated on Dec 23, 2016 n/a
calculated values,
restated on Dec 23, 2016 n/a
calculated values,
Balance SheetBS data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (5 items missing)
No data available for the selected time periods
in million USD FY '14FY '15FY '16
Assets
Cash and cash equivalents
n/a
329
165
Accounts receivable, net
n/a
329
401
Inventories, net
n/a
370
395
Income taxes receivable
n/a
6
9
Prepaid expenses and other
n/a
16
22
Total current assets
n/a
1,049
991
Capital assets
n/a
877
984
Intangible assets
n/a
276
248
Deferred financing costs
n/a
74
0
Deferred tax assets
n/a
1
30
Goodwill
n/a
284
282
Investments
n/a
15
12
Other long-term assets
n/a
40
44
Total assets
n/a
2,615
2,590
Liabilities and owners' equity
Short-term borrowings
n/a
0 400000
0 0
Accounts payable and accrued liabilities
n/a
462 461800000
394 393600000
Income taxes payable
n/a
9 9000000
7 6600000
Deferred revenues - short-term
n/a
106 105900000
154 154200000
Current portion of long-term debt
n/a
21 21200000
20 19500000
Total current liabilities
n/a
598 598300000
574 573900000
Long-term debt
n/a
2,647 2646700000
2,049 2049200000
Deferred revenues
n/a
75 75200000
102 102300000
Deferred tax liabilities
n/a
79 79100000
67 67100000
Other long-term liabilities
n/a
80 79900000
146 145500000
Total liabilities
n/a
3,479 3479200000
2,938 2938000000
Commitments and contingencies
n/a
0 0
0 0
Ordinary Shares
n/a
0 0
2 1600000
Additional paid in capital
n/a
0 0
591 591400000
Membership interests
n/a
30 30000000
0 0
Accumulated deficit
n/a
-821 -820500000
-842 -842100000
Accumulated other comprehensive loss
n/a
-74 -73700000
-99 -99300000
Total shareholders'
n/a
-864 -864200000
-348 -348400000
Total members' deficit
n/a
2,615 2615000000
2,590 2589600000
Remarks restated on n/a restated on Dec 23, 2016 n/a restated on Jun 9, 2017 n/a
Cash Flow StatementCF data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (3 items missing)
No data available for the selected time periods
in million USD FY '14FY '15FY '16
Net income (loss) from continuing operations
-117
35
35
Depreciation and amortization
80
108
113
Non-cash interest
25
17
25
Change in other long-term assets and liabilities
-10
-19
-13
Deferred income taxes
-15
-10
-37
Amortization of deferred revenues
-44
-221
-264
Stock-based compensation expense
10
14
22
Return on capital from equity investment
0
0
1
Impairment
10
4
0
Foreign exchange (gain) loss on debt
0
-2
0
Other
-2
5
-1
Payment of original issue discount
-17
0
0
Excess tax benefit from share-based payment arrangements
0
-8
0
Net change in non-cash working capital balances
-26
-27
-176
Gain on sale of third party investment
0
-16
0
Increase in deferred revenues
83
263
357
Cash provided by operating activities of continuing operations
-25
142
61
Cash (used in) provided by operating activities of discontinued operations
50
43
-3
Cash provided by operating activities
25
185
58
Additions to capital assets
-82
-147
-206
Proceeds from sale of capital assets
5
7
0
Return of capital from equity investment
1
0
2
Equity investment in related party
0
-5
0
Acquisitions, net of cash acquired
-380
-170
0
Proceeds on sale of third party investment
0
21
0
Cash used in investing activities of continuing operations
-455
-294
-203
Cash (used in) provided by investing activities of discontinued operations
-11
206
-3
Cash used in investing activities
-467
-88
-207
Proceeds from long-term borrowings
2,092
804
41
Repayment of debt
-61
-20
0
Cash paid to acquire Patheon shares, net of amounts reinvested in Patheon Holdings
-889
0
0
Increase in deferred financing costs
-674
-93
-592
Redemption of note payable issued as a distribution to member
0
0
-51
Capital contribution
0
0
1
Proceeds on issuance of ordinary shares, net
0
0
585
Cash distribution to members from proceeds obtained from the issuance of the Senior PIK Toggle Notes
0
-538
0
Excess tax benefit from share-based payment arrangements
0
8
0
Cash distribution to shareholders for spinoff of subsidiary
0
-12
0
Cash provided by financing activities of continuing operations
468
149
-16
Cash used in financing activities of discontinued operations
0
-1
0
Cash provided by financing activities
468
148
-16
Effect of exchange rate changes on cash and cash equivalents
-3
-1
1
Net change in cash and cash equivalents during the period
23
244
-164
Remarks
restated on Dec 23, 2016 n/a
calculated values,
restated on Dec 23, 2016 n/a
calculated values,
restated on Dec 23, 2016 n/a
calculated values,
Some of the data shown on this page is provided for free by IEX
Sumo